What Are Telomeres? Chromosome Caps, Aging, and Cancer

A telomere is a stretch of repetitive DNA at each end of a chromosome, and it exists because cells cannot fully copy the very tip of a linear DNA molecule. Every time a human cell divides, its telomeres lose roughly 50 to 200 nucleotides. When they fall short enough, the cell stops dividing, which is one reason normal cells in a dish have a finite number of divisions. An enzyme called telomerase can rebuild telomeres, and cancer cells very often switch it back on. This article explains how that works and where the popular claims about telomeres and aging go too far.

The copying problem at the end of the chromosome

Start with a fact about the machinery that duplicates DNA. The enzyme that builds new strands, DNA polymerase, can only add nucleotides to an existing stretch of nucleic acid. It cannot begin a strand from nothing, so the cell first lays down a short RNA primer to give it something to extend. It also works in one direction only, adding to the 3' end of the growing strand.

That one-way rule is fine for one of the two strands, the leading strand, which can be built in a single continuous run. The other strand, the lagging strand, is built backward in short pieces, each started from its own primer. When the cell removes the last primer at the very end of the chromosome, there is nothing upstream for polymerase to extend into the gap. A short stretch of the template at the tip stays uncopied. For a fuller walk through the enzymes involved, see the DNA replication and genetics explainer.

Think of a photocopier whose paper feed grips the page by its top edge. It copies nearly everything, but the strip of paper the rollers are holding never gets printed. Copy the copy, and the missing strip grows. A chromosome behaves the same way: each round of replication leaves the end slightly shorter than the one before.

Who noticed first

This logic was worked out twice, independently. A review of telomere history in the journal literature attributes the first statement of the "end replication problem" to Alexey Olovnikov in 1971, who reasoned that chromosomes should shorten with every replication cycle and proposed that this could cause the limit on cell division that Leonard Hayflick had described. James Watson reached the same problem in 1972 (see the history in this review on PubMed Central). Olovnikov's connection to cell aging is the reason the idea lasted. The tip of a chromosome was not just a bookkeeping oddity; it looked like a counter.

Why the loss would be catastrophic without a buffer

If the shortened tip held genes, every division would cost the cell information. Cells avoid this by placing no genes at the end. The end is a disposable run of repeats, so the erosion eats into filler before it reaches anything useful. The National Human Genome Research Institute's glossary describes a telomere in just these terms: a region of repetitive DNA at the end of a chromosome that protects it from fraying or tangling, and that gets slightly shorter each time a cell divides.

What a telomere is made of

Human telomeres consist of the sequence TTAGGG repeated over and over. The review of telomere and telomerase therapeutics describes telomeres as containing double-stranded TTAGGG DNA. A human cell has 46 chromosomes, so it carries 92 of these ends, and each one is a long tract of the same six-letter motif.

A tract of repeats on its own would not protect anything. A cell has to hide the end of a chromosome from its own repair systems, because a free DNA end looks exactly like a break, and the cell's response to a break is to glue ends together or stop the cell cycle. A set of proteins called shelterin binds the telomere repeats and does this job. The same review lists the members: TRF1, TRF2, POT1, RAP1, TIN2, and TPP1. Together they shield the end so that the repair machinery leaves it alone.

The analogy everyone uses, and where it breaks

The standard comparison is the plastic aglet on a shoelace. Without it the lace frays; with it the lace holds together. That captures the protective role. It fails in two ways. An aglet never gets shorter as you use the shoe, whereas a telomere erodes with each division, which is the entire point of the story. And an aglet is inert, while a telomere is an actively maintained structure with a set of dedicated proteins attached.

A better picture is a candle wick being trimmed a little with each use. The wick has no job except to be burned first. As long as some remains, the candle works. When it is gone, the flame reaches the candle itself.

The Hayflick limit: cells that count their own divisions

In the early 1960s, Leonard Hayflick and Paul Moorhead set out to grow human cells in culture for long periods. The prevailing belief at the time, which went back to Alexis Carrel's chick-heart cultures in the early twentieth century, was that cells taken from an animal could be kept dividing indefinitely if you gave them the right medium. According to the Embryo Project Encyclopedia's account of Hayflick's work, Hayflick cultured 25 strains of fetal cells and noticed that some of them stopped dividing after about 50 cell population doublings. The cells were not dead. They kept metabolizing, but they did not divide any more.

Their paper, "The serial cultivation of human diploid cell strains," appeared in Experimental Cell Research in 1961. The general range now quoted for normal human cells is 40 to 60 doublings, though the exact number depends on the cell type, the donor's age, and the culture conditions. The ceiling later got the name Hayflick limit.

From a curiosity to a mechanism

For years nobody knew what the counter was. Olovnikov's 1971 proposal pointed at chromosome ends, but it took experiments to show it. The same review on PubMed Central notes that Calvin Harley and colleagues, including Carol Greider, showed that telomeres shorten in human fibroblasts as the cells divide, and that later work found expressing telomerase prevents the shortening and extends the cells' lifespan. That pair of observations turned a clever idea into an experimentally supported mechanism.

The measurements put numbers on it. According to the therapeutics review, telomeres lose about 50 to 200 nucleotides per replication cycle, and replicative senescence, the state where a cell permanently stops dividing, sets in when telomeres reach roughly 4 to 6 kilobases. The authors call this checkpoint mortality stage 1, or M1.

Senescence is a brake, not a death

A senescent cell is alive. It has exited the cell cycle, and it often changes what it secretes, but it is neither dividing nor dying. That matters, because the brake protects the body. A cell with badly shortened telomeres has probably divided many times, and every division was a chance for an error. Stopping it early removes a candidate for becoming a tumor.

Not every cell obeys the brake. Cells that have lost checkpoint proteins such as p53 or p16/RB can ignore the M1 signal and keep dividing while their telomeres wear down. The therapeutics review describes what follows: a second stage, M2 or crisis, marked by genomic instability, chromosome fusions and breakages, and massive cell death. Rarely, a cell in crisis reactivates telomerase, stabilizes its telomeres, and becomes immortal. That route is how a damaged cell can turn into a cancer line.

Telomerase: the enzyme that rebuilds the tip

If telomeres only ever shortened, no species could pass chromosomes to its offspring. A lineage of germ cells would run out of chromosome after a few dozen generations. Something must put the repeats back, and that something is telomerase.

Telomerase has two core parts. TERT is the catalytic subunit, a reverse transcriptase, meaning an enzyme that builds DNA from an RNA template. TERC is an RNA molecule that carries the template. According to the therapeutics review, the template sequence in TERC is 3'-CAAUCCCAAUC-5', which TERT reads to add TTAGGG repeats onto the 3' strand of the chromosome end. In effect, the enzyme brings its own mold.

Where telomerase is switched on

Most adult tissues do not have much of it. The same review reports that telomerase activity is high in fetal and newborn stages and then falls to extremely low levels or disappears from the neonatal period onward, with exceptions in highly regenerative cell types, including hematopoietic, epidermal, and gastrointestinal cells. Germline tissues have it, and a few stem cell populations show some activity. The pattern makes sense: cells that must keep dividing for a lifetime, or pass chromosomes to the next generation, need a way to maintain their ends.

For the biology of how such cells choose their fates in the first place, the stem cell explainer covers the decision logic.

How the enzyme was found

The discovery came from an unglamorous organism, a pond ciliate called Tetrahymena. According to the Embryo Project's timeline of the telomere experiments, Elizabeth Blackburn and Joseph Gall published a paper in 1978 on a tandemly repeated sequence at the ends of Tetrahymena's ribosomal RNA genes. In 1982, Jack Szostak and Blackburn put these Tetrahymena ends onto linearized yeast plasmids. Yeast added its own DNA to them, which suggested that telomeres are conserved across very different organisms.

The next step came from a graduate student. When Carol Greider joined Blackburn's lab in 1984, the two developed a procedure using Tetrahymena extracts and radiolabeled nucleotides, and it revealed an enzyme that adds telomere DNA to a primer. They published it in 1985, under the name telomere terminal transferase, later shortened to telomerase. In 1987 they showed that treating the extract with RNase stopped telomere lengthening, which demonstrated that the enzyme contains an RNA component that serves as a template. In 1989 Greider sequenced that RNA and proposed how it adds nucleotides.

Blackburn, Greider, and Szostak shared the 2009 Nobel Prize in Physiology or Medicine for this body of work.

Year	Step	Who
1961	Normal human cells stop dividing after about 50 doublings in culture	Hayflick and Moorhead
1971 to 1972	The end replication problem formulated, and tied to cell aging	Olovnikov, Watson
1978	Tandem repeats found at the ends of Tetrahymena rDNA	Blackburn and Gall
1982	Tetrahymena ends function on yeast chromosomes	Szostak and Blackburn
1985	Telomerase activity detected in Tetrahymena extracts	Greider and Blackburn
1987 and 1989	Telomerase found to carry an RNA template, then the RNA sequenced	Greider and Blackburn
1998	Telomerase added to normal human cells extends their division capacity	Bodnar and colleagues
2009	Nobel Prize for telomeres and telomerase	Blackburn, Greider, Szostak

The 1998 experiment that closed the loop

If telomere shortening causes the Hayflick limit, then restoring telomerase to normal cells should lift the limit. In 1998, Andrea Bodnar and colleagues, working at UT Southwestern and Geron Corporation, introduced the gene for the human telomerase catalytic subunit into two kinds of normal telomerase-negative human cells: retinal pigment epithelial cells and foreskin fibroblasts. As reported in Science, the cells kept longer telomeres, divided well beyond the point where controls senesced, exceeded their normal lifespan by at least 20 doublings, and kept a normal karyotype. The authors concluded that this established a causal link between telomere shortening and cellular senescence in culture.

The wording matters. The cells in this study were tested in dishes, not in people, and the experiment showed an extension of division capacity, not immortality or a longer human life.

Telomerase and cancer: the same enzyme, a different job

A tumor is a population of cells that have escaped normal limits on division. A cell that divides without end would run its telomeres down to crisis unless it also solves the length problem. Cancer cells solve it, and in most cases they do so by bringing telomerase back.

The therapeutics review states that telomere dysfunction and telomerase reactivation are observed in approximately 90 percent of human cancers. Most of the rest rely on a different strategy, alternative lengthening of telomeres, or ALT, a recombination-based mechanism that copies telomere DNA from one chromosome end to another. The review notes that some telomerase-negative cancers, such as sarcomas and some lymphomas, use ALT.

A specific mutation that does it

In 2013, two groups reported in Science that a large share of melanomas carry mutations in the promoter of the TERT gene, the stretch of DNA that controls how much TERT is made. One of the papers reported such mutations in 50 of 70 melanomas, and showed that they create new binding sites for a family of transcription factors and raise TERT transcription by two- to fourfold in reporter assays. Later work found recurrent TERT promoter mutations in several other cancer types. The mutation does not change the enzyme; it turns up the volume on the gene.

This is a neat illustration of how cancer evolves. A cell that happens to acquire a promoter mutation gains the ability to keep its telomeres, and so outlasts its neighbors. For a broader account of how mutations accumulate into a tumor, see the explainer on what causes cancer.

Why this is not a simple recipe for long life

An obvious thought is that if short telomeres limit cells and telomerase fixes that, more telomerase should mean healthier tissues. The cancer data point the other way. A cell with unlimited division capacity is exactly what a tumor needs. Researchers have to weigh the benefit of longer telomeres against the risk of giving damaged cells the means to keep going.

Human genetics shows the trade-off. Gao and colleagues in 2020 built a genetic risk score for blood-cell telomere length from 17 variants identified in a genome-wide study of up to 78,592 people, and then tested it against cancer in the UK Biobank. In their analysis a genetic profile of longer telomeres was linked to higher risk of several cancers and shorter telomeres to lower risk, including multiple myeloma, chronic lymphocytic leukemia, and malignant melanoma, while a suggestive, statistically marginal association ran the other way for leukemia. The authors concluded that telomeres played diverse roles in different types of cancers. Mendelian randomization, the method they used, treats inherited gene variants as a natural experiment, but it rests on assumptions that cannot be fully checked, and the study measured telomere length in blood cells rather than in the affected tissues. You can read the full paper on PubMed Central.

What telomere length does and does not say about aging

Telomere shortening is part of how cells age, and it is a reasonable candidate for a biological clock. Beyond that point, claims quickly outrun evidence.

What the evidence supports

In culture, telomere length controls division capacity, and telomerase can restore it, as the Bodnar experiment showed. In people with inherited defects in telomere maintenance, the consequence is severe disease in tissues that renew rapidly (see the next section). In some species and tissues, telomeres shorten with age. These are firm findings.

A cloned sheep offers a vivid case. Dolly, the first mammal cloned from an adult cell, was made from a donor cell that had already aged in a living animal and then spent time in culture. A 1999 report in Nature found her telomeres were significantly shorter than those of sheep her age, and the authors linked the shortening to the age of the donor cell and the time it spent in culture. The sheep otherwise looked normal for her breed and age, and the researchers noted that they could not say whether she would reach a critical length during her life. The story of the experiment itself is in the Dolly the Sheep cloning article.

What it does not support

The jump from "telomeres shorten in cells" to "telomere length predicts how long a person will live" is where the trouble starts. Three problems recur.

• Blood is not the body. Most human studies measure telomeres in white blood cells, which are easy to sample. Those cells divide a lot, so their telomeres reflect their own history, and they may not mirror telomeres in the heart, brain, or liver.
• Association is not causation. A person with short telomeres may also smoke, be ill, or carry inflammation that both shortens telomeres and affects health. Without genetic or experimental designs, one cannot tell which came first.
• Direction is not constant. As the Gao study shows, the genetic evidence runs both ways depending on the cancer, so "longer is better" is not a safe summary.

For a broader view of why cells and tissues age, including mechanisms that have nothing to do with telomeres, the site's articles on why we age and the science of aging are a better map than any single biomarker. The question of which interventions have evidence behind them is treated in the article on longevity interventions.

When telomere maintenance fails in people

The clearest evidence that telomeres matter in human health comes from rare inherited disorders. Dyskeratosis congenita is the best-known telomere biology disorder. Reviews of the condition describe mutations in telomerase components, including TERC and TERT, that impair telomerase and shorten telomeres, which shortens the lifespan of cells in tissues that renew rapidly, such as bone marrow. A review in Hematology/Oncology Clinics of North America reported that mutations in 13 genes involved in telomere maintenance account for about 70 percent of cases.

One feature of these disorders is called anticipation: because a child can inherit shortened telomeres from a parent, disease severity can increase in each successive generation. That fits the mechanism. If the length you start with is already reduced, the cell reaches its limit sooner.

These disorders are a mirror image of cancer. In one, telomerase is too weak and tissues run out of divisions. In the other, telomerase is too strong or reactivated and cells fail to stop.

Common misunderstandings about telomeres

"Telomeres are the aging clock." They are one clock among several. Cells also accumulate DNA damage, altered gene regulation, and damaged proteins. A tissue can age for reasons unrelated to how many divisions its cells have undergone, and cells that rarely divide, such as most neurons, are poor candidates for a division counter.

"Telomerase means immortality." Telomerase prevents one kind of limit. A cell with working telomerase can still stop because of DNA damage, stress, or other signals, and a tumor cell with working telomerase is a disease, not a success story.

"Short telomeres mean you are older than your birthday." Telomere length can differ between people of the same age, and a single measurement in blood is a noisy readout. The idea of a precise "biological age" from telomeres is not supported by the evidence discussed above.

"Telomeres shorten because cells divide, so only dividing cells matter." True as far as it goes, but this includes the immune system and the lining of the gut and skin, which divide for a lifetime. That is why these tissues are the ones hit first in telomere biology disorders.

The takeaway

Telomeres exist because of a quirk of DNA copying: the tip of a linear chromosome cannot be fully duplicated, so the cell puts a buffer of disposable repeats there and tolerates its slow erosion. That erosion works as a counter that limits how many times normal cells divide, which is a useful guard against runaway growth. Telomerase, discovered in a pond ciliate, resets the counter in germline and some stem cells, and cancers reactivate it, which is why the same enzyme is both essential to life and a hallmark of tumors. The honest summary for aging is narrower than the headlines: telomere shortening is a real cellular mechanism, but telomere length in a blood sample is a weak and sometimes contradictory predictor of how a person will fare. The cell biology is settled; the extrapolation to lifespan is not. For the surrounding concepts, from how cells divide to genetics and aging, the Complete Biology Guide is the hub.

Frequently asked questions

Q: What is the difference between a telomere and telomerase? A: A telomere is the stretch of repeated DNA, TTAGGG in humans, at the end of a chromosome. Telomerase is the enzyme, made of a TERT protein and a TERC RNA template, that can add those repeats back. The telomere is the structure being protected; telomerase is one of the tools that maintains it.

Q: How much do telomeres shorten with each cell division? A: According to a review of telomere and telomerase therapeutics, telomeres lose about 50 to 200 nucleotides per replication cycle. Replicative senescence, the point at which normal cells stop dividing, occurs when telomeres reach roughly 4 to 6 kilobases. The exact numbers vary by cell type and individual.

Q: What is the Hayflick limit? A: It is the finite number of times a normal human cell can divide in culture before it stops. Leonard Hayflick and Paul Moorhead reported it in 1961, with some of their fetal cell strains stopping after about 50 population doublings. The commonly quoted range is 40 to 60 doublings. Telomere shortening is the best-supported explanation.

Q: Do cancer cells have telomerase? A: Most do. Telomere dysfunction and telomerase reactivation are observed in approximately 90 percent of human cancers. Some cancers, including certain sarcomas and lymphomas, instead use alternative lengthening of telomeres, a recombination-based way to extend chromosome ends without telomerase.

Q: Can lengthening telomeres extend human life? A: That has not been shown. Adding telomerase to normal human cells in culture extended their division capacity by at least 20 doublings in a 1998 study, but that was in dishes. In people, genetic evidence on telomere length and cancer runs in different directions depending on the cancer, so longer telomeres are not simply protective.

Q: Why did Dolly the sheep have shorter telomeres? A: A 1999 analysis found her telomeres significantly shorter than those of sheep her age. The authors linked this to the age of the donor cell and the time it spent in culture before nuclear transfer. Dolly looked physiologically normal for her breed and age, and the researchers could not say whether she would reach a critical length.

Q: Which tissues are most affected when telomere maintenance fails? A: Tissues whose cells divide throughout life, such as bone marrow, skin, and the gut lining. In dyskeratosis congenita, mutations in telomerase components shorten telomeres and reduce the lifespan of cells in these highly proliferative tissues.

Sources

• NHGRI Talking Glossary: Telomere, National Human Genome Research Institute.
• Telomere and Telomerase Therapeutics in Cancer, review on PubMed Central (telomere sequence, shelterin, telomerase structure, senescence and crisis, roughly 90 percent of cancers).
• Leonard Hayflick (1928- ), Embryo Project Encyclopedia, Arizona State University.
• Elizabeth Blackburn, Carol Greider and Jack Szostak's Telomere and Telomerase Experiments (1982-1989), Embryo Project Encyclopedia.
• Telomere history review, PubMed Central PMC4021592 (Hayflick, Olovnikov, Watson, Harley and Greider).
• Assessing the Relationship Between Leukocyte Telomere Length and Cancer Risk/Mortality in UK Biobank and TCGA, Gao and colleagues, Frontiers in Genetics, 2020.